Acrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at KeyCorp

Equities researchers at KeyCorp assumed coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a report issued on Friday,Briefing.com Automated Import reports. The firm set an “overweight” rating on the stock.

A number of other equities analysts have also commented on ACRV. BMO Capital Markets reduced their price target on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Acrivon Therapeutics in a research note on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $23.67.

Acrivon Therapeutics Price Performance

Acrivon Therapeutics stock opened at $5.79 on Friday. The firm has a market capitalization of $180.30 million, a P/E ratio of -2.14 and a beta of 0.77. The stock has a fifty day moving average price of $6.35 and a two-hundred day moving average price of $7.35. Acrivon Therapeutics has a 52-week low of $3.19 and a 52-week high of $11.90.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new position in shares of Acrivon Therapeutics during the fourth quarter worth $40,000. Dimensional Fund Advisors LP bought a new position in Acrivon Therapeutics during the second quarter worth about $58,000. Barclays PLC grew its stake in Acrivon Therapeutics by 51.2% in the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after acquiring an additional 11,273 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Acrivon Therapeutics by 548.3% in the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock worth $238,000 after acquiring an additional 28,748 shares in the last quarter. Finally, State Street Corp raised its position in shares of Acrivon Therapeutics by 26.4% during the third quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after purchasing an additional 47,233 shares during the period. Institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.